
Daewoong files diabetes drug Envlo in 7 additional countries
Daewoong Pharmaceutical said it has submitted regulatory filings for its novel diabetes drug Envlo (ingredient: enavogliflozin) in seven additional countries -- six in Latin America plus Russia -- as part of its global expansion strategy. Daewoong …